Company Overview of ImmusanT, Inc.
ImmusanT, Inc., a biotechnology company, develops treatment and diagnostic and monitoring tools to manage patients with celiac disease. The company offers Nexvax2, a peptide-based therapeutic vaccine that is designed to re-establish patients’ tolerance to the toxic effects of gluten, a protein in wheat, barley, and rye and allow them to return to a normal diet. ImmusanT, Inc. was founded in 2010 and is based in Cambridge, Massachusetts with clinical trials in New Zealand, Australia, and the United States.
One Kendall Square
Cambridge, MA 02139
Founded in 2010
Key Executives for ImmusanT, Inc.
Founder, Chief Executive Officer, President and Director
Chief Financial Officer and Secretary pro tem
Director of Finance and Operations
Senior Scientific/Technical Advisor and Member of Scientific Advisory Board
Compensation as of Fiscal Year 2014.
ImmusanT, Inc. Key Developments
ImmusanT, Inc. Presents at 13th Annual BIO Investor Forum, Oct-07-2014
Sep 9 14
ImmusanT, Inc. Presents at 13th Annual BIO Investor Forum, Oct-07-2014 . Venue: The Palace Hotel, San Francisco, CA 94105, United States.
ImmusanT Names Ferdinand E. Massari as Chief Medical Officer
Sep 9 13
ImmusanT announced that Ferdinand E. Massari, MD has joined the biopharmaceutical company as Senior Vice President, Development and Chief Medical Officer. Dr. Massari will oversee the clinical development program for the therapeutic vaccine Nexvax2(R) for celiac disease and its companion diagnostic, as well as future development programs for other autoimmune diseases. Massari has over 20 years of experience in all stages of drug development and comes to ImmusanT having most recently served as a consultant providing product candidate evaluation and clinical plan development services to companies and investors. Previously, Dr. Massari was Global Head and Vice President of Clinical and Medical Affairs at Shire Human Genetic Therapies, where he was responsible for the oversight of global development of products to treat rare genetic disorders. Earlier, Dr. Massari served as Senior Vice President of Drug Development and Chief Medical Officer at Coley Pharmaceutical Group where he oversaw the development of novel therapeutics for hepatitis C infection and lupus. Dr. Massari has held executive positions at Pfizer where he led clinical programs for ZYVOX (linezolid), one of the most successful hospital antibiotics to date.
Similar Private Companies By Industry
Recent Private Companies Transactions
December 19, 2014
Most Searched Private Companies
Sponsored Financial Commentaries